



Tests you can trust

Name : Varsha Charankar (42Y/F)



Date : 17 Sep 2025

Test Asked : C153, C125 + 1 Others

Report Status: Complete Report



First National Diagnostic Chain to have
100% of its Labs with NABL Accreditation[#]



Your reports are digitally verifiable

Scan the QR code inside the report to check authenticity of reported values

QR code will remain active for 30 days from report release date

Accredited by



NABL From 2005[#]



ISO 9001: 2015 - From 2015



CAP From 2007⁻

Processed At :
D-37/1, TTC MIDC, Turbhe, Navi
Mumbai - 400703



📍 Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. ☎ 9870666333 📩 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation*

Patient Name : VARSHA CHARANKAR (42Y/F) Tests Done : C153,C125,T3-T4-USTSH
Referred By : SELF
Sample Collected At : MyMDDr, Ganga Cascade,
Office No. 04, Lane 5 A,
North Main Road, Koregaon Park,

Report Availability Summary

Note: Please refer to the table below for status of your tests.

✓ 3 Ready 🕒 0 Ready with Cancellation ⟳ 0 Processing ✗ 0 Cancelled in Lab

TEST DETAILS

REPORT STATUS

T3-T4-USTSH	Ready ✓
CA-125	Ready ✓
CA 15.3	Ready ✓

📍 Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. ☎ 9870666333 📩 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation*

Patient Name : VARSHA CHARANKAR (42Y/F)

Referred By : SELF

Sample Collected At : MyMDDr, Ganga Cascade,
Office No. 04, Lane 5 A,
North Main Road, Koregaon Park,

Sample Collected on (SCT) : 17 Sep 2025 17:16

Sample Received on (SRT) : 18 Sep 2025 03:31

Report Released on (RRT) : 18 Sep 2025 06:16

Sample Type | Barcode : SERUM | EJ123488

TEST NAME	TECHNOLOGY	VALUE	UNITS
CA 15.3	E.C.L.I.A	10	U/mL

Bio. Ref. Interval. :-

<=28.5 U/mL

Clinical Significance:

1. CA 15.3 is elevated in about 30% of women with localized breast cancer and in about 75% of those with metastatic breast cancer
2. CA 15.3 also may be elevated in Healthy people and in individuals with other cancers or diseases, Such as Colorectal Cancer, Lung Cancer, Cirrhosis, Hepatitis, and Benign Breast Disease.
3. In General, the higher the CA 15-3 level the more advanced the Breast Cancer and the larger the Tumor Burden.
4. Samples should not be taken from patients receiving therapy with high biotin doses (i.e >5 mg/day) until atleast 8 hrs following the last biotin administration, as this may interfere with the result.
5. In few cases, interference due to extremely high titres of antibodies to analyte - specific antibodies, streptavidin or ruthenium can occur.
6. The results should be assessed in conjunction with patient medical history , clinical examination and other findings.

Reference -

- Duffy MJ, CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem, 1999;36:579-586
- Kit Insert


Please correlate with clinical conditions.

Method:- Fully Automated Electrochemiluminescence Sandwich Immunoassay

Tests Done : CA 15.3,CA-125,T3-T4-USTSH



Dr Arshiya MD(Path)



Dr Ritika Khurana
MD(Path)



Scan QR to verify(valid for
30 days from release time)

📍 Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. ☎ 9870666333 📩 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation*

Patient Name : VARSHA CHARANKAR (42Y/F)

Referred By : SELF

Sample Collected At : MyMDDr, Ganga Cascade,
Office No. 04, Lane 5 A,
North Main Road, Koregaon Park,

Sample Collected on (SCT) : 17 Sep 2025 17:16

Sample Received on (SRT) : 18 Sep 2025 03:31

Report Released on (RRT) : 18 Sep 2025 06:16

Sample Type | Barcode : SERUM | EJ123488

TEST NAME	TECHNOLOGY	VALUE	UNITS
CA-125	E.C.L.I.A	5.23	U/mL

Bio. Ref. Interval. :-

<=35 U/mL

Clinical Significance:

1. CA-125 is used to monitor therapy during treatment for Ovarian Cancer. CA125 is also to detect or monitor whether there is a recurrence of cancer or malignancy after surgical removal of tumor or radiation therapy or chemotherapy (antineoplastic drugs).
2. This test is sometimes used to follow High-Risk women who have a family history of Ovarian Cancer. CA-125 may normally be increased in early pregnancy and during menstruation. It can also be increased in diseases such as Pelvic Inflammatory Disease or Endometriosis and sometimes in Hepatitis and Cirrhosis of the liver.
3. Samples should not be taken from patients receiving therapy with high biotin doses (i.e >5 mg/day) until atleast 8 hrs following the last biotin administration, as this may interfere with the result.
4. In few cases, interference due to extremely high titres of antibodies to analyte - specific antibodies, streptavidin or ruthenium can occur.
5. For Diagnostic Purpose, Results should always be assessed in conjunction with the patients medical history, Clinical Examination and other findings.

Reference

- O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene : an extracellular superstructure dominated by repeat sequences. Tumor Biol 2001; 22 (6): 348-366.
- Kit insert


Please correlate with clinical conditions.

Method:- Fully Automated Electrochemiluminescence Sandwich Immunoassay

Tests Done : CA 15.3, CA-125, T3-T4-USTSH



Dr Arshiya MD(Path)



Dr Ritika Khurana
MD(Path)

📍 Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. ☎ 9870666333 📩 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : VARSHA CHARANKAR (42Y/F)

Referred By : SELF

Sample Collected At : MyMDDr, Ganga Cascade,
Office No. 04, Lane 5 A,
North Main Road, Koregaon Park,

Sample Collected on (SCT) : 17 Sep 2025 17:16

Sample Received on (SRT) : 18 Sep 2025 03:31

Report Released on (RRT) : 18 Sep 2025 06:16

Sample Type | Barcode : SERUM | EJ123488

TEST NAME	TECHNOLOGY	VALUE	UNITS	Bio. Ref. Interval.
TOTAL TRIIODOTHYRONINE (T3)	E.C.L.I.A	133	ng/dL	80-200
TOTAL THYROXINE (T4)	E.C.L.I.A	7.04	μg/dL	4.8-12.7
TSH - ULTRASENSITIVE	E.C.L.I.A	4.79	μIU/mL	0.54-5.30

The Biological Reference Ranges is specific to the age group. Kindly correlate clinically.

Method :

T3,T4 - Fully Automated Electrochemiluminescence Competitive Immunoassay

USTSH - Fully Automated Electrochemiluminescence Sandwich Immunoassay

Pregnancy reference ranges for TSH/USTSH :

Trimester || T3 (ng/dl) || T4 (μg/dl) || TSH/USTSH (μIU/ml)

1st || 83.9-196.6 || 4.4-11.5 || 0.1-2.5

2nd || 86.1-217.4 || 4.9-12.2 || 0.2-3.0

3rd || 79.9-186 || 5.1-13.2 || 0.3-3.5

References :

1. Carol Devilia, C I Parhon. First Trimester Pregnancy ranges for Serum TSH and Thyroid Tumor reclassified as Benign. Acta Endocrinol. 2016; 12(2) : 242 - 243

2. Kulhari K, Negi R, Kalra DK et al. Establishing Trimester specific Reference ranges for thyroid hormones in Indian women with normal pregnancy : New light through old window. Indian Journal of Contemporary medical research. 2019; 6(4)

Disclaimer : Results should always be interpreted using the reference range provided by the laboratory that performed the test. Different laboratories do tests using different technologies, methods and using different reagents which may cause difference. In reference ranges and hence it is recommended to interpret result with assay specific reference ranges provided in the reports. To diagnose and monitor therapy doses, it is recommended to get tested every time at the same Laboratory.

~~ End of report ~~

Tests Done : CA 15.3,CA-125,T3-T4-USTSH



Dr Arshiya MD(Path)



Dr Ritika Khurana
MD(Path)



Scan QR to verify(valid for
30 days from release time)

CONDITIONS OF REPORTING

- v The reported results are for information and interpretation of the referring doctor only.
- v It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- v Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- v Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- v Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- v This report is not valid for medico-legal purpose.
- v Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the total amount of invoice for the services provided and paid for.
- v Thyrocare Discovery video link :- <https://youtu.be/nbdYeRgYyQc>

EXPLANATIONS

- v Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- v **Name** - The name is as declared by the client and recorded by the personnel who collected the specimen.
- v **Ref.Dr** - The name of the doctor who has recommended testing as declared by the client.
- v **Labcode** - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- v **Barcode** - This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- v **SCP** - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by the client.
- v **SCT** - Specimen Collection Time - The time when specimen was collected as declared by the client.
- v **SRT** - Specimen Receiving Time - This time when the specimen reached our laboratory.
- v **RRT** - Report Releasing Time - The time when our pathologist has released the values for Reporting.
- v **Reference Range** - Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- v Values out of reference range requires reconfirmation before starting any medical treatment.
- v Retesting is needed if you suspect any quality shortcomings.
- v Testing or retesting should be done in accredited laboratories.
- v For suggestions, complaints, clinical support or feedback, write to us at customersupport@thyrocare.com or call us on **022-3090 0000**

Preventive Healthcare is now at your fingertips!





Download Thyroapp Now



Launching
JaanCh
For a closer look at your health with



Doctor-Curated Specialised Packages All Under One Roof




Heart

Fever

Cancer

Women's - Reproductive Health



Thyroid

Diabetes

STDs

Skin Care

Hair Fall

Thyrocare
Tests you can trust

* T&C Apply, #As on 5th December 2024 (Applicable for all company owned labs except Bhagalpur & Vijayawada),
* As per survey on doctors' perception of laboratory diagnostics (IJARIIT, 2023), -Mumbai Reference Lab is CAP Accredited